Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

BACKGROUND: The administration of second- or third-generation anti-CD19 chimeric antigen receptor (CAR) T cells has remarkably improved the survival of patients with relapsed or refractory B cell malignancies. However, there are limited clinical results from fourth-generation CAR-T cell therapy, and...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Immunol
Glavni autori: Zhou, Xuan, Tu, Sanfang, Wang, Chunsheng, Huang, Rui, Deng, Lan, Song, Chaoyang, Yue, Chunyan, He, Yanjie, Yang, Jilong, Liang, Zhao, Wu, Anqin, Li, Meifang, Zhou, Weijun, Du, Jingwen, Guo, Zhenling, Li, Yongqian, Jiao, Cheng, Liu, Yuchen, Chang, Lung-Ji, Li, Yuhua
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2020
Teme:
Immunology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731732/
https://ncbi.nlm.nih.gov/pubmed/33329526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.564099
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items